WO2002085376A3 - A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress - Google Patents

A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress Download PDF

Info

Publication number
WO2002085376A3
WO2002085376A3 PCT/CA2002/000568 CA0200568W WO02085376A3 WO 2002085376 A3 WO2002085376 A3 WO 2002085376A3 CA 0200568 W CA0200568 W CA 0200568W WO 02085376 A3 WO02085376 A3 WO 02085376A3
Authority
WO
WIPO (PCT)
Prior art keywords
asa
hypertension
production
treatment
superoxide anion
Prior art date
Application number
PCT/CA2002/000568
Other languages
French (fr)
Other versions
WO2002085376A2 (en
Inventor
Champlain Jacques De
Rong Wu
Midaoui Adil El
Original Assignee
Univ Montreal
Champlain Jacques De
Rong Wu
Midaoui Adil El
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montreal, Champlain Jacques De, Rong Wu, Midaoui Adil El filed Critical Univ Montreal
Priority to AU2002250756A priority Critical patent/AU2002250756A1/en
Publication of WO2002085376A2 publication Critical patent/WO2002085376A2/en
Publication of WO2002085376A3 publication Critical patent/WO2002085376A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to a new method for reducing vascular, cardiac and colonic tissue O2- generation by lowering the NAD(P)H oxidase activity of these tissues in normal and hypertensive subjects using ASA, nimesulide and indomethacin. Although ASA did not show any acute effect in vitro, chronic oral treatment or chronic incubation with ASA significantly lowered the O¿2?- basal or NAD(P)H activated production in aorta and smooth muscle cells from normotensive and hypertensive rats. These effects were dose-dependent and needed more than 3 days to onset in vivo condition. ASA treatment significantly improved the impaired aortic relaxation response to acetylcholine in SHR and significantly attenuated the age-dependent development of hypertension in young SHR. In another model of hypertension and insulin resistance induced by high glucose feeding, which was also found to be associated with a higher production of superoxide anion in tissues from the cardiovascular system, chronic ASA treatment was found to prevent simultaneously the development of hypertension, insulin resistance and the production of superoxide anion. Finally, in another hypertension model induced by the chronic administration of angiotensin II which has the property to activate NAD(P)H oxidase and to enhance the superoxide production in vessels, the concomitant treatment with ASA was also found to simultaneously prevent the development of hypertension and the enhanced superoxide anion production.
PCT/CA2002/000568 2001-04-19 2002-04-19 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress WO2002085376A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002250756A AU2002250756A1 (en) 2001-04-19 2002-04-19 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28450501P 2001-04-19 2001-04-19
US60/284,505 2001-04-19

Publications (2)

Publication Number Publication Date
WO2002085376A2 WO2002085376A2 (en) 2002-10-31
WO2002085376A3 true WO2002085376A3 (en) 2003-03-06

Family

ID=23090451

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/000568 WO2002085376A2 (en) 2001-04-19 2002-04-19 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress

Country Status (2)

Country Link
AU (1) AU2002250756A1 (en)
WO (1) WO2002085376A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097459A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
US11510967B2 (en) 2017-09-08 2022-11-29 Eli Lilly And Company Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992020343A1 (en) * 1991-04-03 1992-11-26 Gunderson Medical Foundation, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
US5593971A (en) * 1990-05-15 1997-01-14 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593971A (en) * 1990-05-15 1997-01-14 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
WO1992020343A1 (en) * 1991-04-03 1992-11-26 Gunderson Medical Foundation, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AVANZINI FAUSTO ET AL: "Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients.", AMERICAN JOURNAL OF HYPERTENSION, vol. 13, no. 6 Part 1, June 2000 (2000-06-01), pages 611 - 616, XP001097790, ISSN: 0895-7061 *
DATABASE MEDLINE [online] June 2000 (2000-06-01), DHALLA N S ET AL: "Role of oxidative stress in cardiovascular diseases.", XP002209148, Database accession no. NLM10872549 *
JOURNAL OF HYPERTENSION. ENGLAND JUN 2000, vol. 18, no. 6, June 2000 (2000-06-01), pages 655 - 673, ISSN: 0263-6352 *
LOPEZ-FARRE A ET AL: "Acetylsalicylic acid treatment improves the endothelium-dependent vasorelaxative response in spontaneously hypertensive rats.", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 12, no. 9, 1997, Annual Congress of the European Renal Association and the European Dialysis and Transplant Association;Geneva, Switzerland; September 21-24, 1997, pages A52, XP001095114, ISSN: 0931-0509 *
PODHAISKY H-P ET AL: "Aspirin protects endothelial cells from oxidative stress - possible synergism with vitamin E", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 417, no. 3, 17 November 1997 (1997-11-17), pages 349 - 351, XP004261482, ISSN: 0014-5793 *
WANNA FADY S ET AL: "Simultaneous manipulation of the nitric oxide and prostanoid pathways reduces myocardial reperfusion injury.", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol. 110, no. 4 PART 1, 1995, pages 1054 - 1062, XP001098581, ISSN: 0022-5223 *

Also Published As

Publication number Publication date
WO2002085376A2 (en) 2002-10-31
AU2002250756A1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
Barton et al. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension
Baluchnejadmojarad et al. Beneficial effect of aqueous garlic extract on the vascular reactivity of streptozotocin-diabetic rats
HK1071313A1 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
Yanes et al. Systemic arterial pressure response to two weeks of Tempol therapy in SHR: involvement of NO, the RAS, and oxidative stress
EP1733734A3 (en) Placental alkaline phosphatase to control diabetes
Obatomi et al. Effects of African mistletoe extract on blood pressure in spontaneously hypertensive rats
IL91572A (en) Pharmaceutical compositions for treating conditions appearing after vascular damage comprising ace inhibitors
WO2002085376A3 (en) A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
Yamamoto et al. Effects of cilostazol, an antiplatelet agent, on axonal regeneration following nerve injury in diabetic rats
WO2007005774A3 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
CN108619138A (en) The compound and application thereof of angiotensin receptor antagonist and enkephalinase inhibitor
CN115645402A (en) Application of aranidipine in preparation of medicine for treating or preventing acute myocardial infarction
Wei et al. Therapeutic Benefits of Pomegranate Flower Extract: A Novel Effect That Reduces Oxidative Stress and Significantly Improves Diastolic Relaxation in Hyperglycemic In Vitro in Rats
UA85548C2 (en) Use of aqueous extract of red vine leaves for preventing transition from clinically insignificant early stages of chronic venous insufficiency to stages i, ii or iii
WO2002043566A3 (en) Devices and methods for treating low blood sugar levels
JP5063878B2 (en) Composition for prevention / treatment of digestive system disease containing hydrogen sulfide
Uchida et al. Quinapril Treatment Restores The Vasodilator Action Of Insulin In Fructose‐Hypertensive Rats
JP2007112735A (en) Analgesic composition
Malabu et al. Acute hyperinsulinemia increases neuropeptide Y concentrations in the hypothalamic arcuate nucleus of fasted rats
Miyazato et al. A gap junction blocker inhibits isolated whole bladder activity in normal rats and rats with partial bladder outlet obstruction
Ilechukwu et al. The role of oxidative stress in diabetes mellitus: a 24-year review
Mateescu et al. 16 Copper Amine Oxidases as Antioxidant and Cardioprotective Agents
Rauws et al. Activated charcoal in tricyclic drug overdoses
Morita et al. Response of renal sympathetic nerve activity to parabolic flight-induced gravitational change in conscious rats
WO2005097102A3 (en) Method to treat chronic heart failure and/or elevated cholesterol levels

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP